BiDil savings programs: focused on patient access
At Arbor, we want to help your patient with access to BiDil treatment.
That's why we have 2 different savings programs to choose from.
Prescription Savings Card:
FREE start, followed by low copays*
- Patients may pay as little as $0 for their first fill of Bidil (up to 90 tablets).
- Insured patients may pay as little as $25 for refills 2 through 12.
Not intended for use by health care providers in the state of Vermont.
E-Z Rx program:
Extra-low copays through participating independent pharmacies†
Insured patients may pay just $10 and cash patients just $50 for each monthly supply of BiDil (up to 90 tablets per month). Copay requirements apply.†
More than 3200 participating pharmacies
More than 600,000 prescriptions for Arbor products filled
Locate a participating pharmacy for BiDil savings
Pharmacies should be contacted in advance to ensure they have BiDil in stock.
Arbor Pharmaceuticals' Patient Assistance Program
For more information about the Arbor Pharmaceuticals Patient Assistance Program, please email email@example.com.
IMPORTANT SAFETY INFORMATION
BiDil is contraindicated in patients who are allergic to organic nitrates, or who take a phosphodiesterase type 5 (PDE5) inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil, or soluble guanylate cyclase (sGC) stimulator (riociguat). Concomitant use can cause hypotension.
INDICATIONS AND USAGE
BiDil is indicated for the treatment of heart failure as an adjunct to standard therapy in self-identified black patients to improve survival, to prolong time to hospitalization for heart failure, and to improve patient-reported functional status. There is little experience in patients with NYHA class IV heart failure. Most patients in the clinical trial supporting effectiveness (A-HeFT) received a loop diuretic, an angiotensin converting enzyme inhibitor or an angiotensin II receptor blocker, and a beta blocker, and many also received a cardiac glycoside or an aldosterone antagonist.
IMPORTANT SAFETY INFORMATION
BiDil is contraindicated in patients who are allergic to organic nitrates, or who take phosphodiesterase type 5 (PDE5) inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil, or soluble guanylate cyclase (sGC) stimulator (riociguat). Concomitant use can cause hypotension.
WARNINGS AND PRECAUTIONS
Hydralazine hydrochloride has been reported to cause a drug-induced systemic lupus erythematosus (SLE) syndrome. Symptoms and signs usually regress when hydralazine hydrochloride is discontinued.
Symptomatic hypotension, particularly with upright posture, may occur with even small doses of BiDil. Hypotension is most likely to occur in patients who have been volume or salt depleted; correct prior to initiation of BiDil. Hydralazine hydrochloride can cause tachycardia and hypotension potentially leading to myocardial ischemia and angina, particularly in patients with hypertrophic cardiomyopathy.
Hydralazine hydrochloride has been associated with peripheral neuritis, evidenced by paresthesia, numbness, and tingling, which may be related to an antipyridoxine effect. Pyridoxine should be added to BiDil therapy if such symptoms develop.
Most common adverse reactions (> 5% more on BiDil than on placebo) were headache and dizziness.
Reference: 1. Data on file. Arbor Pharmaceuticals, LLC.